Analyst Review Alert: Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Analysts are weighing in on how Amicus Therapeutics, Inc. (NASDAQ:FOLD) , might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.9. The stock is rated as buy by 3 analysts, with 3 outperform and 2 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 7.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.33 a share, which would compare with $-0.27 in the same quarter last year. They have a high estimate of $-0.28 and a low estimate of $-0.38. Revenue for the period is expected to total nearly $170.00K.

For the full year, 7.00 Wall Street analysts forecast this company would deliver earnings of -1.35 per share, with a high estimate of $-1.07 and a low estimate of $-1.65. It had reported earnings per share of $-1.19 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $4.21M.

The analysts project the company to maintain annual growth of around 45.90% percent over the next five years as compared to an average growth rate of 16.94% percent expected for its competitors in the same industry.

Among the 8 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for FOLD is $12.63 but some analysts are projecting the price to go as high as $17.00. If the optimistic analysts are correct, that represents a 153 percent upside potential from the recent closing price of $6.71. Some sell-side analysts, particularly the bearish ones, have called for $9.00 price targets on shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) .

In the last reported results, the company reported earnings of $-0.27 per share, while analysts were calling for share earnings of $-0.24. It was an earnings surprise of -12.50%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson’s disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.